Christian Doppler Laboratory for High-Content Structural Biology and Biotechnology, Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus Vienna Biocenter 5, 1030, Vienna, Austria.
Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, 1121, Vienna, Austria.
ChemMedChem. 2021 Dec 6;16(23):3576-3587. doi: 10.1002/cmdc.202100458. Epub 2021 Oct 8.
The NRF2 transcription factor is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoting chemo-resistance, tumor growth, and metastasis by activating its downstream target genes. Hence, inhibition of NRF2 promises to be an attractive therapeutic strategy to suppress cell proliferation and enhance cell apoptosis in cancer. Direct targeting of NRF2 with small-molecules to discover protein-DNA interaction inhibitors is challenging as it is a largely intrinsically disordered protein. To discover molecules that bind to NRF2 at the DNA binding interface, we performed an NMR-based fragment screen against its DNA-binding domain. We discovered several weakly binding fragment hits that bind to a region overlapping with the DNA binding site. Using SAR by catalogue we developed an initial structure-activity relationship for the most interesting initial hit series. By combining NMR chemical shift perturbations and data-driven docking, binding poses which agreed with NMR information and the observed SAR were elucidated. The herein discovered NRF2 hits and proposed binding modes form the basis for future structure-based optimization campaigns on this important but to date 'undrugged' cancer driver.
NRF2 转录因子是细胞氧化应激反应的关键调节剂,作为一种肿瘤抑制因子。异常激活 NRF2 通过激活其下游靶基因,促进化疗耐药、肿瘤生长和转移。因此,抑制 NRF2 有望成为一种有吸引力的治疗策略,以抑制癌症中的细胞增殖并增强细胞凋亡。由于 NRF2 主要是一种无序的蛋白质,因此直接用小分子靶向 NRF2 以发现蛋白-DNA 相互作用抑制剂具有挑战性。为了在 DNA 结合界面发现与 NRF2 结合的分子,我们对其 DNA 结合域进行了基于 NMR 的片段筛选。我们发现了几个与 DNA 结合位点重叠的弱结合片段。我们通过目录 SAR 开发了最有趣的初始命中系列的初始结构-活性关系。通过结合 NMR 化学位移扰动和数据驱动对接,阐明了与 NMR 信息和观察到的 SAR 一致的结合构象。在此发现的 NRF2 命中和提出的结合模式为未来基于结构的优化活动奠定了基础,这是一个重要但迄今为止“未开发”的癌症驱动因素。